2500 Stock Overview
Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Venus Medtech (Hangzhou) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.62 |
| 52 Week High | HK$14.94 |
| 52 Week Low | HK$3.74 |
| Beta | 0.55 |
| 1 Month Change | 0% |
| 3 Month Change | -0.71% |
| 1 Year Change | -61.61% |
| 3 Year Change | -92.66% |
| 5 Year Change | n/a |
| Change since IPO | -86.95% |
Recent News & Updates
Recent updates
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?
Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?
May 29What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You
May 11Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook
Apr 07Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?
Oct 12Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates
Sep 04We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate
Jul 28Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth
Mar 29Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?
Jan 09Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation
Dec 01We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow
Aug 16A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)
Jul 12Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth
Apr 26Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%
Apr 05Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate
Mar 07What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?
Feb 14
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner
Jan 19Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?
Dec 29Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?
Dec 29Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?
Dec 08Shareholder Returns
| 2500 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -0.5% |
| 1Y | -61.6% | -27.9% | 19.9% |
Return vs Industry: 2500 underperformed the Hong Kong Medical Equipment industry which returned -51.3% over the past year.
Return vs Market: 2500 underperformed the Hong Kong Market which returned -16.7% over the past year.
Price Volatility
| 2500 volatility | |
|---|---|
| 2500 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2500 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2500's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,006 | Lin Haosheng Lim | www.venusmedtech.com |
Venus Medtech (Hangzhou) Inc. engages in the research, development, clinical development, manufacturing, and commercialization of transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension.
Venus Medtech (Hangzhou) Inc. Fundamentals Summary
| 2500 fundamental statistics | |
|---|---|
| Market cap | HK$2.46b |
| Earnings (TTM) | -HK$1.31b |
| Revenue (TTM) | HK$491.35m |
5.0x
P/S Ratio-1.9x
P/E RatioIs 2500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2500 income statement (TTM) | |
|---|---|
| Revenue | CN¥452.11m |
| Cost of Revenue | CN¥101.03m |
| Gross Profit | CN¥351.07m |
| Other Expenses | CN¥1.56b |
| Earnings | -CN¥1.21b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.76 |
| Gross Margin | 77.65% |
| Net Profit Margin | -267.18% |
| Debt/Equity Ratio | 23.4% |
How did 2500 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/19 08:38 |
| End of Day Share Price | 2023/11/22 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Haoyuan Zhang | China Merchants Securities (HK) Co., Ltd |